Maximizing Current Therapies and Exploring Future Directions as PARP Inhibitors Take the Stage in Prostate Cancer
| Overview / Abstract: |
This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts. |
|
Expiration |
Apr 05, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Podcast, Webinar / Webcast / Video |
|
Credits / Hours |
1.50 AMA PRA Category 1 Credit(s) |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Neeraj Agarwal, MD; Celestia Higano, MD, FACP; Daniel Petrylak, MD; Patrick G. Pilié, MD; Neal Shore, MD, FACS |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Pfizer. |
|
Keywords / Search Terms |
ACHL Neeraj Agarwal, Patrick Pilie, Celestia Higano, Daniel Petrylak, Neal Shore, PARP, inhibitor, PARP inhibitor, prostate cancer, DNA, Mechanism of action, MOA, PARP1, PARPi, BRCA, Olaparib, Talazoparib, emerging, combination, regimens, metastatic, Castration-Resistant, rucaparib, TRITON2, Niraparib, Veliparib, DNA-repair gene defects, DRD, Molecular Biomarkers, NCCN, somatic variants, germline, DNA sequencing, genetic counseling Free CE CME |
|